Gatifloxacin sold under the brand names Gatiflo Tequin and Zymar is an antibiotic of the fourth-generation fluoroquinolone family that like other members of that family inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections having licensed the medication from Kyorin Pharmaceutical Company of Japan.
This page contains content from the copyrighted Wikipedia article "Gatifloxacin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
